We are hereby submitting audited standalone and consolidated financial results for the quarter ended 31st March, 2026
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts more than Nifty Microcap 250 and 9.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kilitch Drugs India reported strong Q4 FY26 results with standalone net profit of Rs 1,400 lakhs, up 23% YoY, on total income of Rs 7,311 lakhs. For the full year, standalone net profit grew 4% to Rs 3,240 lakhs on revenue of Rs 20,242 lakhs. Consolidated revenue jumped 18% YoY to Rs 24,671 lakhs with net profit of Rs 2,950 lakhs. The company issued bonus shares in 1:1 ratio during Q4, doubling share capital. Capital work-in-progress tripled to Rs 14,002 lakhs indicating major expansion. Trade receivables increased significantly, creating higher expected credit loss provisions. Statutory auditors issued unmodified (unqualified) opinions on both standalone and consolidated financials.
Solid operational performance with strong quarterly growth; bonus issue dilutes EPS but rewards shareholders. Rising receivables and heavy capex warrant monitoring. Clean audit opinion is positive for investor confidence.